Trial Profile
A Real Life Study Investigating the Use and Outcomes of Belatacept Maintenance Immunosuppression (MIS) Using OPTN/UNOS Kidney Transplant Registry
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jul 2020
Price :
$35
*
At a glance
- Drugs Belatacept (Primary) ; Ciclosporin; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 03 Jun 2020 Results (n=1737) assessing patterns of belatacept use and incidence of PTLD in kidney transplant recipients in clinical practice using data from OPTN database(UNOS) from two clinical studies (NCT01656343 and a US-based observational study) presented at the 2020 American Transplant Congress
- 13 Jul 2018 New trial record
- 06 Jun 2018 Results presented at the 2018 American Transplant Congress.